Dynavax Technologies Corporation Stock News

The consensus price target hints at a 73.9% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni

Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed t

The average of price targets set by Wall Street analysts indicates a potential upside of 70.6% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionabl

FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.

IAS, DVAS and KTOS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 4, 2023.

CVI, JJSF, IAS, DVAX and EB have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2023.

Dynavax Technologies (DVAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n

As a rule of thumb, you want to buy quality names in the market, which admittedly rules out several ideas for best stocks under $15 for June. It's not that cheap securities don't exist.

EMERYVILLE, Calif. , May 30, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod

Dynavax Technologies (DVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.22 per share a year ago.

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, t

Viatris (VTRS) reports in-line Q4 earnings but misses on sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

Bausch (BHC) reports an increase in earnings and sales in the fourth quarter as the company???s business revives in the second half.

JMP Securities has decided to maintain its Market Outperform rating of Dynavax Technologies (NASDAQ:DVAX) and raise its price target from $22.00 to $25.00. Shares of Dynavax Technologies are trading d